hotspot -WSS

hotspot

author：hotspot 2025-10-01 21:36:01 - browse：26165

European Medicines Agency Suffers Cyber Attack in Amsterdam — Paulo Amorim / VWPics via AP Images

LONDON — European regulators on Friday reiterated their view that an ALS treatment from Amylyx Pharmaceuticals should not be approved, likely dooming the drug’s chances for now.

A European Medicines Agency committee had initially recommended against approving the drug, known as Albrioza, in June. Friday’s confirmation of that position came after the company appealed the decision. While the European Commission officially decides whether to approve a new medicine, it almost always follows the committee’s guidance. The final decision is expected to be made before the end of the year.

The drug, which won approval last year in the United States and is marketed Relyvrio, is designed to slow the progression of the fatal neurological condition. In its pivotal trial, patients who received the drug over 24 weeks scored about two points better on a 48-point scale of symptoms than those who got a placebo, indicating the drug slowed disease progression.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Beach reads and more: STAT's 2023 summer book list

entertainment

WSS

Dozens of Pride flags vandalized at Stonewall monument in NYC, 3rd time this month: Police

More tobacco lobbyists active in statehouses

H5N1 bird flu found in pasteurized milk: what we know

Why 40% Americans with Parkinson’s don’t see a neurologist

Palantir health business leans on meeting customers’ needs

BIO: Crackdown on China pharma industry would threaten U.S. drug supply

explore

hotspot

Wikipedia

Drug repurposing or repositioning? The language matters

Why ADHD is under

Guidelines to prevent youth baseball injuries need more muscle

Charles Manson follower Leslie Van Houten released from prison after 53 years

Medical records are filled with copy

It's time to get medical device identifiers over the finish line

Duchenne breakthrough therapy leaves behind pioneering families

Petition to FDA: Get the lead out of consumer hair dyes

Novavax promises a turnaround & Lilly roils the obesity market

Dogs on Prozac: What pet anti

explore

MultiPlan and major insurers sued for alleged medical price

Retired US general questions alleged Putin, Prigozhin meeting

Element Biosciences CEO lays out genome sequencing strategy

California’s proposed $25 per hour health care minimum wage

Health care needs a new profession: neuroimaging counseling

How the political right came to back psychedelics to treat trauma

focus

Wikipedia

entertainment

knowledge